Lipustobart

利普苏拜单抗

Report date: 2025/01/15 15:53:38

Base Information

Drug NameLipustobart
Drug Alias Name注射用重组人源化抗PD-1单抗recombinant humanized anti-PD-1 monoclonal antibodyLZM-009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThymoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesLivzon(Group) Pharmaceutical Factory
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBright Peak Therapeutics IncLivzon Mabpharm Inc
Inactive CompaniesLivzon Pharmaceutical Group Inc
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThymoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A